AR050187A1 - Uso de inhibidores de alk 5 para modular o inhibir la actividad de miostatina, a fin de lograr mayor acumulacion de tejido magro en animales - Google Patents

Uso de inhibidores de alk 5 para modular o inhibir la actividad de miostatina, a fin de lograr mayor acumulacion de tejido magro en animales

Info

Publication number
AR050187A1
AR050187A1 ARP050103119A ARP050103119A AR050187A1 AR 050187 A1 AR050187 A1 AR 050187A1 AR P050103119 A ARP050103119 A AR P050103119A AR P050103119 A ARP050103119 A AR P050103119A AR 050187 A1 AR050187 A1 AR 050187A1
Authority
AR
Argentina
Prior art keywords
animals
miostatine
magro
alk
modulate
Prior art date
Application number
ARP050103119A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR050187A1 publication Critical patent/AR050187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

Métodos para aumentar el tejido muscular en animales. En un aspecto el método comprende la administracion de una cantidad eficaz de un inhibidor del receptor ALK5, tal como se muestra en formula (1), a un animal, durante un tiempo suficiente para povocar el efecto deseado. Una alimentacion para ganado y un equipo para aumentar el deposito de musculo en animales. Un método para la produccion de carne y un método para disminuir el tejido graso en animales.
ARP050103119A 2004-07-29 2005-07-27 Uso de inhibidores de alk 5 para modular o inhibir la actividad de miostatina, a fin de lograr mayor acumulacion de tejido magro en animales AR050187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59235904P 2004-07-29 2004-07-29

Publications (1)

Publication Number Publication Date
AR050187A1 true AR050187A1 (es) 2006-10-04

Family

ID=35595039

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103119A AR050187A1 (es) 2004-07-29 2005-07-27 Uso de inhibidores de alk 5 para modular o inhibir la actividad de miostatina, a fin de lograr mayor acumulacion de tejido magro en animales

Country Status (14)

Country Link
US (1) US20060194845A1 (es)
EP (1) EP1771171A1 (es)
JP (1) JP2008506787A (es)
CN (1) CN101031294A (es)
AR (1) AR050187A1 (es)
AU (1) AU2005280496B2 (es)
BR (1) BRPI0513914A (es)
CA (1) CA2576734C (es)
MX (1) MX2007001118A (es)
NO (1) NO20071113L (es)
PE (1) PE20060729A1 (es)
TW (1) TW200616621A (es)
WO (1) WO2006025988A1 (es)
ZA (1) ZA200700681B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
US20100144865A1 (en) * 2007-05-04 2010-06-10 Jana Pickova Compound feed for aquaculture
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101684457B (zh) * 2009-07-27 2013-01-09 中国科学院广州生物医药与健康研究院 I型转化生长因子受体抑制剂在产生诱导多能干细胞中的应用及其方法
CA2831827A1 (en) * 2011-04-05 2012-10-11 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
EP3711771A1 (en) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2022511112A (ja) 2018-12-11 2022-01-28 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
AU2020385400A1 (en) 2019-11-22 2022-06-09 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
WO2022104071A2 (en) * 2020-11-13 2022-05-19 The Jackson Laboratory Therapeutics targeting transforming growth factor beta family signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1147413B1 (en) * 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
ES2187473T3 (es) * 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
AU2005280496B2 (en) 2009-10-08
WO2006025988A1 (en) 2006-03-09
PE20060729A1 (es) 2006-08-12
CN101031294A (zh) 2007-09-05
CA2576734A1 (en) 2006-03-09
NO20071113L (no) 2007-02-27
TW200616621A (en) 2006-06-01
US20060194845A1 (en) 2006-08-31
CA2576734C (en) 2010-03-16
JP2008506787A (ja) 2008-03-06
ZA200700681B (en) 2008-07-30
MX2007001118A (es) 2007-03-15
BRPI0513914A (pt) 2008-05-20
AU2005280496A1 (en) 2006-03-09
EP1771171A1 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
AR050187A1 (es) Uso de inhibidores de alk 5 para modular o inhibir la actividad de miostatina, a fin de lograr mayor acumulacion de tejido magro en animales
BRPI0512274A (pt) derivados de piperazina aril-substituìdos
ECSP21003643A (es) Compuestos antagonistas de pcsk9
CR9716A (es) Bencimidazoles sustituidos como inhibidores de cinasa
ES2422705T3 (es) Proceso para recubrir al polvo comida para animales
RU2015149196A (ru) Соединения sarm и способы их применения
BRPI0817482A2 (pt) agentes terapêuticos para a doença do enxerto versus hospedeiro compreendendo um inbidor do receptor da interleucina 6 como substância ativa
PE20081690A1 (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma
ECSP077318A (es) Analogos de biaril piperazinil-piridina sustituidos
CR6436A (es) Inhibidores de la receptacion de monoaminas para el tratamiento de trastornos del snc
UY32138A (es) Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
AR047992A1 (es) Diaminopirimidinas como antagonistas de p2x3 y p2x2/3
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
NI200500087A (es) Derivados 4-tetrazolyl-4 fenilpiperidina para el tratamiento del dolor
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
PA8851501A1 (es) Compuestos purina
MX346362B (es) Composiciones y metodos para inhibir la adhesion celular o dirigir agentes de diagnostico o terapeuticos a sitios de enlace rgd.
UY30664A1 (es) Derivados de benzacepin-2(ih)-ona
CR8572A (es) Derivados de oxidiazolona como agonistas de la actividad de delta ppar
CY1109840T1 (el) Σπινοσινες για επουλωση πληγων
AR061271A1 (es) Antagonistas de cgrp
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
NI200900023A (es) Análogos de 2-fenoxi pirimidinona
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal